Dapsone: use in immunobullous disorders

Authors

  • Shagufta Shafi

DOI:

https://doi.org/10.66344/jpad.15.2.2005.637

Keywords:

Dapsone, toxicity, dermatitis herpetiformis, linear IgA disease, bullous pemphigoid, cicatricial pemphigoid, bullous SLE, epidermolysis bullosa acquisita, pemphigus.

Abstract

Dapsone and other sulfonamides have been used successfully in the treatment of patients witha variety of blistering skin diseases. The patients most likely to respond to dapsone therapyhave predominantly neutrophilic infiltrate in their skin e.g. dermatitis herpetiformis and linearIgA disease. The precise mechanism of action of dapsone is unknown. In vitro studies haveshown that dapsone can interfere with the production of and response to neutrophilicchemotactants and that it may impair the neutrophils' ability to localize to sites ofinflammation and produce toxic oxygen intermediates. The safe use of dapsone requires anunderstanding of the pharmacology and adverse effects of the drug. Hemolytic anemia andmethemoglobinemia are two of the dose-related adverse effects. Agranulocytosis, motorneuropathy, and dapsone hypersensitivity syndrome are some of the severe idiosyncraticeffects that can occur in patients treated with dapsone. Careful patient selection and closemonitoring of patients during therapy with dapsone are critical elements in the safe andeffective use of dapsone for patients with blistering skin diseases.

Downloads

Published

2016-12-28

How to Cite

1.
Shafi S. Dapsone: use in immunobullous disorders. J Pak Assoc Dermatol [Internet]. 2016Dec.28 [cited 2026May3];15(2):172-81. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/637

Issue

Vol. 15 No. 2 (2005): April - June

Section

Review Articles

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.